Nasdaq Stays Suspension of Trading in deCODE Stock
29 Avril 2009 - 3:26AM
PR Newswire (US)
deCODE shares will continue to trade as usual pending Nasdaq
listing review REYKJAVIK, Iceland, April 28 /PRNewswire-FirstCall/
-- deCODE genetics (NASDAQ:DCGN) announced that it has this evening
received a letter from the Nasdaq Listing and Hearing Review
Council stating that the Council has called for review the April 22
determination of the Nasdaq Listing Qualifications Panel regarding
the delisting of the company's common stock from the Nasdaq Stock
Market. Pending the completion of this review the Council has also
stayed the Panel's proposed suspension of trading in deCODE common
stock mentioned in deCODE's 8-K filing made after the close of the
market this afternoon. The company's stock will therefore continue
to trade as usual on the Nasdaq Capital Market during the review
process. About deCODE deCODE is a biopharmaceutical company
developing drugs and DNA-based tests to improve the treatment,
diagnosis and prevention of common diseases. Its lead therapeutic
programs, which leverage the company's expertise in chemistry and
structural biology, include DG041, an antiplatelet compound being
developed for the prevention of arterial thrombosis; DG051 and
DG031, compounds targeting the leukotriene pathway for the
prevention of heart attack; and DG071 and a platform for other PDE4
modulators with therapeutic applications in Alzheimer's disease and
other conditions. deCODE is a global leader in human genetics, and
has identified key variations in the genome (SNPs) conferring
increased risk of major public health challenges from
cardiovascular disease to cancer. Based upon these discoveries
deCODE has brought to market a growing range of DNA-based tests for
gauging risk and empowering prevention of common diseases. Through
its CLIA-registered laboratory, deCODE offers deCODE T2(TM) for
type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke;
deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for
prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma;
and deCODE BreastCancer, for the common forms of breast cancer.
deCODE is delivering on the promise of the new genetics.SM Visit us
on the web at http://www.decode.com/; on our diagnostics site at
http://www.decodediagnostics.com/; for our pioneering personal
genome analysis service and new focused disease scans, integrating
the genetic variants included in these tests and those linked to
another twenty common diseases, as well as for our new deCODEme
Cardio(TM) and deCODEme Cancer(TM), at http://www.decodeme.com/;
and on our blog at http://www.decodeyou.com/. Any statements
contained in this presentation that relate to future plans, events
or performance are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results, and the timing of
events, to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
among others, those relating to our ability to obtain sufficient
financing to continue as a going concern, the outcome of the review
of the continued listing of our common stock on The Nasdaq Stock
Market, our ability to develop and market diagnostic products, the
level of third party reimbursement for our products, risks related
to preclinical and clinical development of pharmaceutical products,
including the identification of compounds and the completion of
clinical trials, our ability to form collaborative relationships,
the effect of government regulation and the regulatory approval
processes, market acceptance, our ability to obtain and protect
intellectual property rights for our products, dependence on
collaborative relationships, the effect of competitive products,
industry trends and other risks identified in deCODE's filings with
the Securities and Exchange Commission, including, without
limitation, the risk factors identified in our most recent Annual
Report on Form 10-K and any updates to those risk factors filed
from time to time in our Quarterly Reports on Form 10-Q or Current
Reports on Form 8-K. deCODE undertakes no obligation to update or
alter these forward-looking statements as a result of new
information, future events or otherwise. DATASOURCE: deCODE
genetics CONTACT: deCODE genetics, Joy Bessenger, +1-212-481 3891,
, Edward Farmer, +354 570 2819, , or Gisli Arnason, +354 570 1825,
Web Site: http://www.decode.com/
Copyright
Decode Genetics (MM) (NASDAQ:DCGN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Decode Genetics (MM) (NASDAQ:DCGN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Decode Genetics (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Decode Genetics (MM)